Trial Profile
A Study Assessing The Effect Of Alemtuzumab Induction Therapy In Standard Risk Renal Transplant Recipients: An Updated UK Experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 12 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress.